Background review for diagnostic test development for Zika virus infection.
Background review for diagnostic test development for Zika virus infection.
复制标题
DOI：
10.2471/blt.16.171207
复制
发表时间：
2016-08-01
影响因子：
11.1
通讯作者：
Reusken C
中科院分区：
文献类型：
--
作者：
Charrel RN;Leparc-Goffart I;Pas S;de Lamballerie X;Koopmans M;Reusken C
回顾寨卡病毒感染诊断检测的知识状况，并确定弥补当前知识差距所需的研究领域。我们对有关寨卡病毒的已发表文献进行了非系统性回顾，并补充了来自商业诊断测试套件的信息以及与欧洲防备网络研究人员的个人通信信息。该综述涵盖了有关该病毒的地理传播、病原体特征、生命周期和感染动力学的最新知识。在当前爆发菌株的背景下描述和讨论了可用的分子和血清学测试以及生物安全问题。我们确定了以下研究领域，以解决当前的知识差距：(i) 对实验室能力和各国检测寨卡病毒的能力进行紧急评估； (ii) 在有或没有寨卡病毒传播的地区，对现有的分子和血清学检测进行快速、广泛的现场验证，重点是孕妇； (iii) 监测流行的寨卡病毒株的基因组多样性； (iv) 对病毒感染动力学的前瞻性研究，重点是诊断采样（样本类型、组合和时间安排）； (v) 制定分子和血清学检测的外部质量评估，包括对类似病毒和症状群的鉴别诊断。需要促进诊断开发试剂（病毒株和抗原、定量病毒核糖核酸）的可用性。国际实验室需要做出反应，包括制定前瞻性研究方案，以满足最紧迫的信息需求。
To review the state of knowledge about diagnostic testing for Zika virus infection and identify areas of research needed to address the current gaps in knowledge. We made a non-systematic review of the published literature about Zika virus and supplemented this with information from commercial diagnostic test kits and personal communications with researchers in European preparedness networks. The review covered current knowledge about the geographical spread, pathogen characteristics, life cycle and infection kinetics of the virus. The available molecular and serological tests and biosafety issues are described and discussed in the context of the current outbreak strain. We identified the following areas of research to address current knowledge gaps: (i) an urgent assessment of the laboratory capacity and capability of countries to detect Zika virus; (ii) rapid and extensive field validation of the available molecular and serological tests in areas with and without Zika virus transmission, with a focus on pregnant women; (iii) monitoring the genomic diversity of circulating Zika virus strains; (iv) prospective studies into the virus infection kinetics, focusing on diagnostic sampling (specimen types, combinations and timings); and (v) developing external quality assessments for molecular and serological testing, including differential diagnosis for similar viruses and symptom clusters. The availability of reagents for diagnostic development (virus strains and antigens, quantified viral ribonucleic acid) needs to be facilitated. An international laboratory response is needed, including preparation of protocols for prospective studies to address the most pressing information needs.